Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 2, 2011, Pages 235-241

  Hori, S ^a   Jabbar, T ^b   Kachroo, N ^a   Vasconcelos, J C ^a   Robson, C N ^b   Gnanapragasam, V J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Biochemical relapse; Non metastatic; Outcome; Primary androgen deprivation therapy; Prostate cancer; PSA nadir

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER RELAPSE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78751614268     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0877-9     Document Type: Article

References (24)

1. H Akaza Y Homma M Usami Y Hirao T Tsushima K Okada M Yokoyama Y Ohashi Y Aso Prostate Cancer Study Group 2006 Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up BJU Int. 98 573 579 1:CAS:528:DC%2BD28XhtVWru7vL 10.1111/j.1464-410X.2006.06349. x 16925756 (Pubitemid 44185879)
2. EA Benaim CM Pace PM Lam CG Roehrborn 2002 Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer Urology: 59 73 78 10.1016/S0090-4295(01)01440-6 (Pubitemid 34059310)
3. TK Choueiri W Xie AV D'Amico, et al. 2009 Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy Cancer 115 981 987 1:CAS:528:DC%2BD1MXjs1Kjurk%3D 10.1002/cncr.24064 19152438
4. EH Cooper 1992 Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer Prostate 4 125 129 1:STN:280:DyaK383ksVyisg%3D%3D 10.1002/pros.2990210520
5. MR Cooperberg GD Grossfeld DP Lubeck 2003 National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 981 989 10.1093/jnci/95.13.981 12837834
6. MR Cooperberg DP Lubeck SS Mehta, et al. 2003 Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol 170 S21 S25 10.1097/01.ju.0000095025.03331.c6 14610406 (discussion S6-S7) (Pubitemid 37413938)
7. CJ DiBlasio JB Malcolm J Hammett JY Wan MA Aleman AL Patterson RW Wake IH Derweesh 2009 Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience BJU Int 104 1208 1214 10.1111/j.1464-410X.2009. 08593.x 19388987
8. HS Evans H Moller 2003 Recent trends in prostate cancer incidence and mortality in southeast England Eur Urol 43 337 341 10.1016/S0302-2838(03)00085-X 12667713 (Pubitemid 36427451)
9. Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53:68-80
10. C Huggins C Hodges 1941 Studies in prostate cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293 297 1:CAS:528: DyaH3MXkvVCrtw%3D%3D
11. M Hussain CM Tangen C Higano 2006 Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 3984 3990 10.1200/JCO.2006.06.4246 16921051 (Pubitemid 46630748)
12. S Ishikawa MS Soloway R Van der Zwaag B Todd 1989 Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer J Urol 141 1139 1142 1:STN:280:DyaL1M3hslWjsQ%3D%3D 2651713
13. DM Janoff C Peterson S Mongoue-Tchokote, et al. 2005 Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer BJU Int 96 503 507 10.1111/j.1464-410X.2005.05674.x 16104900 (Pubitemid 41224317)
14. J Kawakami JE Cowan EP Elkin DM Latini J DuChane PR Carroll CaPSURE Investigators 2006 Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Cancer 106 1708 1714 10.1002/cncr.21799 16544313
15. C Kwak SJ Jeong MS Park E Lee SE Lee 2002 Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J Urol 168 995 1000 10.1016/S0022-5347(05)64559-4 12187207
16. J Morote E Trilla S Esquena, et al. 2004 Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer Int J Cancer 108 877 881 1:CAS:528:DC%2BD2cXht1CitL0%3D 10.1002/ijc.11639 14712491 (Pubitemid 38112617)
17. J Morote S Esquena JM Abascal, et al. 2005 Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer Int J Biol Markers 20 209 216 1:STN:280:DC%2BD28%2Fht1Sktw%3D%3D 16398402
18. North and Yorkshire Cancer Registry and Information Service. http://www.nycris.nhs.uk
19. MG Oefelein VS Ricchiuti PW Conrad, et al. 2002 Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era Urology 60 120 124 10.1016/S0090-4295(02)01633-3 12100936 (Pubitemid 34722959)
20. AV Schally 2007 Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art BJU Int 100 Suppl 2 2 4 1:CAS:528:DC%2BD2sXpsVCrtbc%3D 10.1111/j.1464-410X.2007.06942.x 17594347 (Pubitemid 46985601)
21. VB Shahinian YF Kuo JL Freeman E Orihuela JS Goodwin 2005 Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 1615 1624 1:CAS:528:DC%2BD2MXjvVymtb8%3D 10.1002/cncr.20955 15742331 (Pubitemid 40490022)
22. N Sharifi JL Gulley WL Dahut 2005 Androgen deprivation therapy for prostate cancer JAMA 294 238 244 1:CAS:528:DC%2BD2MXmtlSlt7g%3D 10.1001/jama.294.2.238 16014598 (Pubitemid 41043794)
23. MS Soloway S Ishikawa R van der Zwaag B Todd 1989 Prognostic factors in patients with advanced prostate cancer Urology 33 53 56 1:STN:280: DyaL1M3isVSjuw%3D%3D 10.1016/0090-4295(89)90107-6 2775378 (Pubitemid 19123267)
24. DW Wilson ME Harper HM Jensen, et al. 1985 A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation Prostate 7 131 141 1:STN:280: DyaL28%2Fhs1Cgsw%3D%3D 10.1002/pros.2990070203 3931066 (Pubitemid 16237916)